Universität zu Köln

Puppe, Julian, van Ooyen, Deborah, Neise, Jeanne, Thangarajah, Fabinshy, Eichler, Christian, Kraemer, Stefan, Pfister, Roman, Mallmann, Peter, Wirtz, Marina and Michels, Guido (2017). Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation. Breast Care, 12 (1). S. 40 - 45. BASEL: KARGER. ISSN 1661-3805

Full text not available from this repository.

Abstract

Background: Chemotherapy with anthracyclines is associated with life-threatening electrocardiographic alterations including corrected QT (QTc) interval prolongation. Patients and Methods: In this study we assessed the effect of epirubicin, cyclophosphamide, and docetaxel (EC-Doc) on the QTc interval in 10 patients with early breast cancer. Cardiac toxicity was assessed with symptoms, transthoracic echocardiography, electrocardiography (ECG), and serum cardiac markers at baseline and after 4 cycles of EC and 4 cycles of docetaxel. To evaluate the influence of interobserver variation, the QTc interval was analyzed by a cardiologist, a gynecologist, and with automated ECG interpretation software. Results: There was a significant QTc prolongation after EC treatment independent of the investigator. In addition, a significant increase in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels was noted after EC treatment. QTc prolongation and NT-proBNP levels normalized after docetaxel treatment. Other biochemical markers were within normal ranges. No clinically relevant effect on left ventricular ejection fraction was observed. Conclusion: This prospective study demonstrated that EC treatment increases the QTc interval and NT-proBNP levels in women with early breast cancer. This effect was reversible and independent of docetaxel administration. Moreover, the treating physician can safely perform QTc interval evaluation as part of clinical routine independent of his/her specialty. Due to the small number of patients, further conclusions are limited at this point. (C) 2017 S. Karger GmbH, Freiburg

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Puppe, Julian UNSPECIFIED UNSPECIFIED UNSPECIFIED van Ooyen, Deborah UNSPECIFIED UNSPECIFIED UNSPECIFIED Neise, Jeanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Thangarajah, Fabinshy UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichler, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kraemer, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, Roman UNSPECIFIED UNSPECIFIED UNSPECIFIED Mallmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Wirtz, Marina UNSPECIFIED UNSPECIFIED UNSPECIFIED Michels, Guido UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-247235
DOI:	10.1159/000455065
Journal or Publication Title:	Breast Care
Volume:	12
Number:	1
Page Range:	S. 40 - 45
Date:	2017
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	1661-3805
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADJUVANT CHEMOTHERAPY; NATRIURETIC PEPTIDES; HEART-FAILURE; THOROUGH QT; TRASTUZUMAB; RISK; DISEASE; ANTHRACYCLINES; VARIABILITY; DYSFUNCTION Multiple languages Oncology; Obstetrics & Gynecology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24723